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Abstract 
Ageing is associated with changes in the nervous system with consequent alterations in some 
neurological examination findings: understanding what is “normal” at different ages is essential 
when evaluating patients. In seminal papers published in 1931, Macdonald Critchley summarised his 
observations and the prevailing evidence on the effects of ageing on, amongst others, sensation, 
reflexes, ocular function, olfaction, movement, and cognition. In this review these observations are 
re-evaluated in light of contemporary evidence. Factors influencing the measurement and 
interpretation of these clinical findings are then discussed, including reproducibility, the influence of 
co-morbidities, secular trends, how “normality” should best be defined, the problems of 
extrapolating group data to individuals, and the influence of pre-symptomatic neurodegenerative 
disease states. The case is made that context is critical, and that combining life course data with 
detailed clinical and biomarker phenotyping is required to understand the determinants of normal 
neurological function associated with ageing. 
 Introduction 
As with all aspects of human physiology, the nervous system alters with ageing. Even in the 
healthiest elderly, there is more neuronal loss, more vascular pathology, and numerous changes at 
the cellular level compared to healthy younger adults. These changes have consequences, and all 
neurologists will recognise that when examining a patient, what can reasonably be determined to be 
“within normal limits” for a healthy 70-year-old differs from that for a healthy 20-year-old. Inherent 
therefore when evaluating any patient is knowledge of what can reasonably be considered to be 
within the normal range at any given age group.  While there is considerable dogma about what 
constitutes “normal” neurological ageing – there can be few neurologists who will not recall being 
told that one can disregard absent ankle jerks or impaired distal vibration sense in somebody in their 
seventies or eighties – the evidence base for such assertions is rather less clear.  
Whilst numerous papers have considered aspects of neurological ageing in isolation, relatively few 
have attempted an overview.  A notable exception are the three seminal papers in the Lancet in 
1931 by Macdonald Critchley, [1,2,3] based on his Goulstonian Lectures to the Royal College of 
Physicians that same year. In these papers he covered the pathological, clinical and cognitive 
changes associated with ageing. 
In Part 1 of this paper, Critchley’s original observations are reviewed and critiqued in light of 
contemporary evidence. In Part 2, some factors relevant to the interpretation of these findings are 
discussed, with particular reference to what might influence what is, or is not, “normal” ageing.   
Part 1:  Macdonald Critchley revisited. 
Dr Macdonald Critchley, CBE (1900–1997) (Figure 1) was one of the foremost neurologists of his era, 
President of the World Federation of Neurology, vice-President of the Royal College of Physicians, 
and author of over two hundred books and papers including seminal works on the parietal lobes, 
aphasia and headache. [4] His prodigious output was based in large part on his detailed and 
meticulous observations of patients. What follows are selected quotations from some of his writings 
on ageing including sensation, reflexes, vision, hearing, taste and smell, gait, hypo- and hyperkinetic 
movements, and cognition, along with a brief review of contemporary evidence for each domain.  
* Figure 1 here  
Sensation   
“The outstanding and perhaps the earliest alteration is seen in respect of vibratory sensibility.  There 
is with advancing years, a progressive impairment of this form of sensation, leading eventually to a 
total loss.  This is demonstrable first at the extremities of the limbs.  Thus vibratory sense may be 
impaired at the fingers and toes only; later it is lost at the wrists and ankles, though it is still present 
proximally”. 
These observations are largely borne out by contemporary studies.  Table 1, adapted from a meta-
analysis of fifty studies, shows results from 9,996 presumed healthy individuals who underwent 
clinical assessment of pain perception, light touch, vibration and joint position sense. [5] Whilst 
people between 18–39 years showed no consistent abnormalities, there was impaired vibration 
sense at the big toe in approximately a third of those aged 60 and above.  By contrast, fewer than 
10% had vibration sense loss at the fingers, with a similar number having impairments of joint 
position sense, light touch and pain perception.  Distal vibration sense loss is therefore confirmed as 
the commonest sensory deficit associated with ageing, but is not universal, being seen in fact in a 
minority of individuals. 
* Table 1 here  
Reflexes 
“Thus [with ageing] the tendon jerks tend to be sluggish and are frequently lost.  The ankle jerks 
illustrate this point especially well; with advancing years, this tendon reflex becomes more and more 
difficult to elicit and finally disappears.  So frequently does this occur, in the absence of other 
neurological manifestations, that one is driven to the conclusion that absence of the ankle jerks in old 
age is without pathological significance”.   
Table 2 shows a summary of reflex tendon loss by age, again from the meta-analysis by Vrancken et 
al. [5]. By the age of 80 years, around one third of healthy people have lost their ankle jerks, with 
only a very small number having lost their knee, triceps and bicep jerks. Again, however, loss of 
ankle jerks is not universal, being retained in the majority of elderly individuals. 
 
* Table 2 here 
 
Vision 
 
“Progressive impairment of visual acuity is, of course, characteristic of advancing age, if we except 
for a moment those cases of myopia which improve as the years pass. Wharthin, indeed, describes 
the three cardinal signs of senescence as sexual neurasthenia, chronic fatigue, and presbyopia 
 
“Alterations in the pupillary reactions are important.  With advancing years there is a progressive 
sluggishness in the response of the pupils, both to light and on accommodation, and ultimately a 
condition of pupillary immobility may occur… 
“Still more often one sees an absence or impairment of the conjugate movements of upwards 
deviations of the eyeballs; lateral and downward movements rarely suffer.  Nystagmus does not 
occur except where focal lesions within the cerebellum happen to be present”.   
Table 3 provides a summary of the prevalence of ocular pathology in adults aged 40 years and older 
in the United States. [6] Blindness occurs in <1% until the age of 80 years, increasing to ~7% 
thereafter; a much greater proportion have impaired vision.  As Critchley observed, myopia declines 
with increasing age, but non-neurological causes of visual impairment including cataract (affecting 
almost two thirds of individuals over eighty) and glaucoma (nearly 10%) are clearly age related.   
* Table 3 here 
Figure 2A shows data for age-related changes in pupil diameter in both the dark- and light-adapted 
eye. [7] Maximum pupil diameter occurs around the age of 20 years, declining thereafter, with 
changes more clearly apparent in the dark-adapted eye. 
Figure 2B shows that saccadic latency to all degrees of amplitude reaches a nadir between ages 30–
50, before progressively increasing; [8] in parallel (Figure 2C), the mean peak saccadic velocity is 
highest in the teenage years, declining progressively thereafter. [8] There is relatively greater 
variability, however, as shown by the increased error bars, in the eighth decade and beyond. Whilst 
the angle of maximal upgaze is lower in the 70s and 80s than earlier, the angle of maximal downgaze 
begins to diminish earlier, from the 60s. [9]  
* Figure 2 A,B,C here 
Hearing   
“Deafness due to inter-current disease of the middle ear is, of course, not uncommon but even in the 
absence of gross aural disease, some degree of impaired auditory acuity is present.  The latter is 
characterised by a loss of hearing or whisper, and for high tones together with shortened bone 
conduction”.  
Figure 3 shows change in the ability to perceive different frequencies between 18 and 55 years. [10] 
As noted by Critchley, age-related decline is much more marked at higher frequencies. 
* Figure 3 here  
Taste and smell  
“The faculties of taste and smell are probably less acute, for most very aged individuals are 
indifferent to the quality of what they eat, provided that the quantity is adequate.  A liking for 
pungent or piquant substances is suggested by the frequent excessive use of condiments”.   
Figure 4 provides normative data using the University of Pennsylvania Smell Inventory Test (UPSIT). 
Sense of smell is relatively stable until 60 years, but declines thereafter. By 65–80 years, ~60% of 
healthy people have a major olfactory deficit (UPSIT score of <19/40); by the age of 80 years or 
above, this proportion is around 80%. [11] 
* Figure 4 here 
Gait 
“The most characteristic type of gait in old age is seen in the marche à petits pas. In the early stages 
it is betrayed by a mere loss of elasticity, some shortening of the steps, and a slight widening of the 
base.  Such a gait may almost be regarded as characteristic of healthy old age. 
“ … it must be remembered that an abnormal gait in this age is frequently the result of disease 
outside the nervous system”.    
Figure 5 illustrates the normal walking speeds at different ages in men and women from the 
Baltimore Longitudinal Study of Aging. [12] Whilst there is very wide variability in the normal walking 
speed between people of the same age and sex, there is a clear and consistent trend for gait 
speed—relatively stable until aged 60 years—to decline thereafter. 
* Figure 5 here 
Parkinsonian signs 
“The forgoing components of extra pyramidal disease – namely flexion attitude, rigidity, poverty of 
movement, and bradykinesis when present in some intensity – constitute a picture of Parkinsonism.  
But it is probably that in some degree these manifestations are present in the majority of all senile 
patients, if we except those that show the more obvious signs of hyperkinesis or motor agitation”.   
A degree of Parkinsonism is common in elderly people, with an estimated overall presence of some, 
often mild, features in 30–40%. [13] Table 4 shows the prevalence of different items of the United 
Parkinson’s Disease Rating Scale (UPDRS) where there is a score of 1/4 (mild symptoms), or 2.  
These data, based on 1,339 people aged >75 years (mean 77) and excluding people with Parkinson’s 
disease, show marked differences in the frequency of abnormalities in different domains: 2% had 
rest tremor, 20% had some axial bradykinesia, and around 30% had some degree of postural 
instability. 
* Table 4 here  
Tremor 
“Senile tremor constitutes the commonest incidence of hyperkinesis, although by no means often 
encountered …  Its usual rate is 100 beats per minute, the common sites for its occurrence at the 
head and lower jaw, the hands and forearms”.  
Tremor in older people has been the subject of considerable recent interest. Figure 6 (graph 
reproduced from Deuschl et al.) shows tremor is minimal up to 40 years increasing thereafter, to a 
prevalence of ~10% by 90 plus. [14] These data suggest that the incidence of hereditary and sporadic 
essential tremor peaks by 50 years, and accounts overall for only 2–3% of tremor in older people.  
The implication therefore is that another form of tremor that the authors term “aging related 
tremor” emerges in midlife, increasing to a prevalence of ~8% by 90 yrs. The exact nature of this 
tremor remains unclear, but it is seems not to be a benign phenomenon, being associated both with 
increasing cognitive impairment and mortality. [14] 
* Figure 6 here 
Chorea   
“Without doubt the term senile chorea has been applied too readily to cases with characteristic 
movements associated with old age.  In order to make this diagnosis, one must be scrupulous to 
exclude: 1) cases associated with a family history of chorea or insanity; 2) cases in which the chorea 
has commenced in middle age and persisted into advanced age; 3) cases of apoplectic onset – usually 
unilateral in their manifestations.  When these criteria rigidly apply, senile chorea is found to be a 
rarity”.   
The decades since Critchley’s papers have led to huge advances in our understanding of chorea. 
Table 5 (adapted from Kimber and Thompson) shows the much wider range of causes than were 
recognised in 1931. [15] It is likely that this means that even fewer cases of chorea will remain 
undiagnosed and reinforces Critchley’s observation that idiopathic “senile chorea” is very rare, if 
indeed it exists at all. 
* Table 5 here 
Cognition   
“Psychic senescence…. (is) the pattern of psychological processes which is to be expected in  healthy 
old age.  The outstanding features include the diminished acuity of memory, or better a loss of 
adherence to recent events; impaired faculty of rapid evocation of events; loss of fluidity; a weakness 
of creative imagination”.   
What is, and what is not, normal cognitive performance with age is the subject of huge investigation. 
Figure 7, reproduced from a review by Hedden and Gabrieli, [16] shows that in broad terms the 
ageing process affects different cognitive domains variably.  Thus, verbal ability is relatively 
preserved (the basis of the National Adult Reading Test as an estimation of premorbid intelligence 
[17]), as is numeracy, whilst, Critchley observed, there is a progressive, slow decline in speed, 
reasoning, spatial skills and episodic memory from aged 25 years onwards.   
* Figure 7 here 
 
Part 2: Interpreting ageing changes  
It is striking that careful clinical observations reported by a single neurologist some 85 years ago are 
largely borne out by contemporary clinical research. Whilst Critchley wrote at length about factors 
that need to be accounted for when interpreting such observations, research in the intervening 
decades has provided further insights, some of which are reviewed below. 
Reproducibility  
Critical to comparing clinical signs between individuals is an understanding of how reproducibly they 
can be elicited; when comparing findings across the life course, it is also vital to know if there is a 
systematic reason why the method of assessment might be affected by age per se. In some 
instances, i.e. with neuropsychological cognitive testing, standard methodologies allow for (albeit 
not always perfect) between- and within-subject comparisons to be made. In routine clinical practice 
and for most of the domains discussed previously this is not the case and there is often huge 
variability in how various tests are elicited and interpreted. For example, O’Keefe et al investigated 
12 people of average age 82 years, half of whom were reported to have absent ankle jerks. [18] They 
compared the “plantar strike” and “tendon strike” methods for obtaining the ankle jerks (Figure 8) 
between and within physicians of different levels of experience.  The median kappa values for intra- 
and inter-observer variability were higher for the plantar strike (0.47 and 0.57) compared to the 
tendon strike method (0.2 and 0.21 respectively) suggesting that the plantar strike is more reliable – 
at least in this age group, where for instance musculoskeletal disease may make positioning the foot 
for the tendon strike more difficult. However, neither method is very reproducible, with the kappa 
values consistent with weak reproducibility for the plantar strike, and minimal reproducibility for the 
tendon strike method.  
*Figure 8 here  
Co-morbidities  
What constitutes a “neurological” sign is not always clear, as Critchley recognised; and in many 
cases, non-neurological factors may influence signs that fall within the broad remit of the 
neurologist. Musculoskeletal disease is self-evidently likely to impair gait; sense of smell is 
influenced by sinus disease and other local pathologies; visual impairment by the presence of 
glaucoma and cataracts; and cognition by mood, pain, and a wide range of prescribed and illicit 
drugs. Some degree of white matter change is almost inevitable with advancing age – and anyone 
attending a neuroradiology case conference will be used to allowance being given for “one or two 
white dots per decade”. Whilst excess white matter disease probably indicates vascular pathology 
and has clinical consequences, its pathological underpinnings vary. As imaging techniques become 
ever more sensitive, more changes are detected; accordingly, how much white matter change is 
really “allowable” for ageing is at least in part arbitrary. [19] 
Importantly, co-morbidities in elderly people are the rule rather than the exception. Thus in the MRC 
National Survey of Health and Development, a representative UK sample recruited at birth in 1946 
and followed prospectively, by the ages of 60–64 years people had on average two medical 
conditions: 54% had hypertension, 31% obesity, 26% hypercholesterolaemia, and 25% either 
diabetes mellitus or impaired glucose tolerance. By contrast only 15% were free from any co-
morbidity [20]. In an unselected sample of individuals over the age of 85, the prevalence of 
hypertension, osteoarthritis, atherosclerosis, and cataract were each around 50%, and ~90% had 
three or more conditions [21].  
Secular trends   
What we consider to be “normal” is not fixed but alters over time.  If one takes life expectancy, 
when Critchley wrote his papers the chance of living to the age of 100 from birth was 2.5% for men 
and 5.1% for women; by 2011 these figures were 26.0 and 33.7% respectively. [22] It is likely 
therefore that 80-year-olds described by Critchley would fall into a “super ageing” category that we 
might now reserve for centenarians.  Lifestyle changes mean that individuals will have different 
exposures depending on their year (and country) of birth. Thus the incidence of smoking has 
radically declined in recent years in high-income countries, and there have been major changes in 
screening for, and treatment of, hypertension, hypercholesterolaemia, and diabetes mellitus. 
Conversely, individuals now in their seventies were brought up in an age of rationing, compared now 
to very readily available high calorie foods with consequent rises in obesity.  
Defining “normality”   
How we define normality in the context of ageing is a debatable question. One approach is to assess 
those who are the best performers in their age group. This approach confirms that there are limits to 
what can be expected with age. Figure 9 illustrates the world record time for running five kilometres 
by age and by sex. [12] Whilst the best performing 80-year-olds still run this distance faster than the 
average runner of any age, peak performance is still seen between the ages of 20–40 years, 
deteriorating slowly to the age of 80 years, and rapidly thereafter.  
* Figure 9 here 
Age-related normative data are commonly used in neuropsychological testing, as illustrated by the 
Recognition Memory tests for Faces (Figure 10). [23] A score of 36/50 on this test is “normal” above 
50 years, but is abnormal (<5%) score below the age of 40. Such normative scores can be based on 
relatively small numbers (e.g. 15–40 people in each of the three groups shown); they are grouped 
into relatively crude age-related groups with everyone over the age of 55 years considered together; 
and importantly assumptions must be made that the individuals these norms are derived from are 
“normal”. 
In other domains, it is not always clear whether, or to what extent to take age into account when 
defining normality. For instance, in the context of brain volume there is debate in the literature as to 
whether hippocampal volume loss is part of normal ageing, occurs only in the context of one or 
more pathological processes, or whether different hippocampal regions are vulnerable to ageing and 
pathology [24]; this has fundamental implications for whether it is appropriate to index brain volume 
against younger individuals – in which case many more elderly people will be determined as 
pathological – or to allow for ageing. 
* Figure 10 here 
Moving from groups to individuals   
Whilst group level data help in understanding the processes underpinning ageing, it is not always 
easy to extrapolate from these to individuals.  With ageing, it is important wherever possible to 
compare an individual’s performance against their premorbid abilities – any clinician will be much 
more concerned about an elderly person presenting with gait difficulties if that person was a regular 
marathon runner until recently, than if they had longstanding walking difficulties. Whilst in the case 
of cognition it is possible at least to some extent to extrapolate premorbid performance by 
estimating years of education or occupation, this can be much more difficult in other domains. Even 
within the range of “normality” it is very likely that individuals have different trajectories of decline, 
likely related to life course exposures, to genetics, and to other co-morbidities. In the case of child 
development, using growth charts allows people to be tracked along their own personal trajectories; 
it would be ideal to have longitudinal data on which to assess individuals’ change over time, but such 
measurements are rarely made outside of research studies. 
Furthermore, in many clinical settings it is often necessary to define what are inevitably arbitrary 
cut-offs for normality or abnormality.  Thus, to define somebody as having amnestic mild cognitive 
impairment – an intermediate state between normal ageing and dementia – requires both decline 
from pre-morbid functioning and “objective memory impairment for age”. [25] If the latter is 
operationalised, as is often done, to define performance below a pre-specified score (e.g. <1.5 SD 
below age-norms), this will inevitably be a lower bar for individuals with premorbid weak memories 
than those with superior abilities. An example of this, reported by Archer et al, was of a very high 
functioning man, a keen chess player, who presented to clinic complaining that he could previously 
think seven moves ahead at chess but could now only manage three or four. [26] Whilst initially 
performing within normal limits on cognitive testing, he declined sufficiently to fulfil criteria for mild 
cognitive impairment two years later. He died of other causes at this stage, and at post-mortem was 
determined to have already advanced Alzheimer’s disease; retrospective review of his scans 
revealed that he had progressive and excess hippocampal atrophy predating the emergence of 
objective impairments (Figure 11).  
* Figure 11 here 
“Normal” ageing contains individuals with presymptomatic neurodegeneration 
As the previous case demonstrates, and is now clear from numerous post-mortem and biomarker 
studies, the pathological change, and in some cases allied symptoms, associated with the core 
neurodegenerative diseases are present and begin to accumulate many years prior to the onset of 
symptoms.  Thus subtle but detectable cognitive decline occurs before the onset of Alzheimer’s 
disease [27]; anosmia precedes the development of both Alzheimer’s disease [28] and Parkinson’s 
disease [29]; REM sleep behaviour disturbance and constipation occur before the onset of 
Parkinson’s disease [29]; and the emergence of subtle Parkinsonian signs may not only predict 
Parkinson’s disease, but also subsequent clinically significant cognitive decline [30]. 
The emergence of biomarkers has allowed the detection of aspects of pathology in vivo that in 
Critchley’s day could only be determined at post-mortem. In the case of cognition, PET (and CSF) 
have shown that over one in three people aged over 70 years have significant -amyloid brain 
pathology; [31] MRI confirms that amyloid positive elderly individuals have excess atrophy, [32] and 
may well develop Alzheimer’s disease should they live long enough. This concept has led to changes 
in diagnostic criteria that, at least on a research basis, now include a pre-symptomatic phase of 
Alzheimer’s disease. [33] Similar findings in people destined to develop neurodegenerative diseases 
on a genetic basis concur with these conclusions [34]. Studies incorporating multiple imaging 
biomarkers are revealing that there may also be a group of heathy elderly people with biomarker 
profiles suggesting non -amyloid brain pathologies – although whether these individuals all have 
pre-symptomatic neurodegenerative diseases, and if so which one(s), is the subject of considerable 
debate [35][36]. These uncertainties aside, the inevitable conclusion from these and numerous other 
studies is that a significant proportion of apparently healthy people who may be recruited as, or 
considered to be, “normal”, will be in the early stages of developing disease. 
 Clinical Relevance?  
Although it is important for a neurologist to determine if the clinical signs they elicit are or are not 
within the normal limits for age, it is also important that the clinical context is taken into account.  
This relates to many features including whether the patient is symptomatic or not; whether signs 
occur in isolation or combination; where there are biomarkers available, whether they are positive 
or not; and what are the consequences of finding pathology. In a recent population study 
investigating polyneuropathy, the combinations of signs – i.e. not just the prevalence of isolated 
vibration sense loss or decreased tendon reflexes – and (in all but a few case) nerve conduction 
studies abnormalities were required to define the presence of a definite polyneuropathy. [36]. Using 
these criteria, 13.2% of those over the age of 80 years had a polyneuropathy; whilst this represents a 
considerably smaller proportion of those with either absent ankle jerks or sensory disturbance alone 
(Tables 1 and 2), importantly 50% of this group were previously undiagnosed, and a potentially 
treatable cause was determined in a proportion. [37].  
Conclusions 
As Critchley elegantly delineated some 85 years ago, ageing is associated with changes within the 
nervous system and some aspects of the nervous system are more vulnerable than others. Ageing is 
associated with accumulation of many pathologies, notably cerebrovascular disease, but also with 
the emergence of neurodegeneration, and often the signs typically associated with “normal” ageing 
and pathology can overlap. In general, ‘within-individual’ changes are likely to be more powerful 
than comparisons between individuals, and longitudinal research studies incorporating life course 
data with detailed clinical phenotyping and biomarkers provide a powerful paradigm for 
understanding the complexity of the ageing process. As and when disease-modifying therapies for 
neurodegenerative diseases become available, using biomarkers to determine the presence of 
specific pathologies will become increasingly important, both to ensure that treatments are given to 
symptomatic people with the pathology in question, but also to determine which elderly people with 
pre-symptomatic disease may benefit most from treatment.   
 
Key Points 
1. Ageing is associated with changes in the nervous system: understanding what is “normal” 
at different ages is important when evaluating patients. 
2. As Macdonald Critchley recognised over 85 years ago, some aspects of the neurological 
examination are more vulnerable to ageing than others, but in no case is decline 
inevitable. 
3. Interpretation of neurological signs in the elderly depends on context: factors that must be 
taken into account include the influence of co-morbidities, the problems of extrapolating 
group data to individuals, and the influence of presymptomatic or asymptomatic disease. 
4. Longitudinal studies incorporating detailed phenotyping, biomarkers and life course data 
are starting to reveal the complexities of the ageing process. 
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